Plain-English translation of NCT05030545 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing a medication called in people who have primary aldosteronism—a condition where the body produces too much of a hormone that raises blood pressure. Researchers want to see whether taking this medication for 6 months can improve how well the heart pumps blood and how blood flows through the heart. The study uses heart imaging tests before and after treatment to measure any improvements.
Primary aldosteronism often damages the heart over time, even when blood pressure is controlled with other drugs. This trial is designed to see whether this medication might offer extra protection for the heart in this specific condition.
You likely qualify if…
You likely don't qualify if…
If you qualify, you'll take daily (at a dose of 50–100 mg, adjusted based on your blood pressure and potassium levels) for 6 months. Before you start and again after 6 months, you'll have two heart imaging tests: an echocardiogram (an ultrasound of your heart) and a cardiac PET scan (a more detailed imaging test that shows blood flow). Your doctor will monitor your blood pressure and potassium levels to make sure the medication is safe for you.
AI-generated summary from trial data · Jun 8, 2026 · Not medical advice
United States